Printer Friendly

Impax confirms patent challenge to generic FENTORA by Cephalon and CIMA Labs.

M2 EQUITYBITES-November 22, 2011-Impax confirms patent challenge to generic FENTORA by Cephalon and CIMA Labs(C)2011 M2 COMMUNICATIONS http://www.m2.com

Impax Laboratories Inc (Nasdaq:IPXL) on Monday confirmed that it had initiated a challenge of the patents listed in the Orange Book in connection with Fentora (fentanyl buccal tablets, 100 mcg, 200 mcg, 400 mcg, 600 mcg and 800 mcg).

Impax had filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of Fentora with the US Food & Drug Administration (FDA). Following receipt of the notice from FDA that Impax's ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owner of its paragraph IV certification.

On 18 November 2011, Cephalon Inc and CIMA Labs Inc filed suit for patent infringement against Impax Laboratories in the District of Delaware. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's generic division, intends to commercialise the product.

Fentora is used to treat 'breakthrough' cancer pain that is not controlled by other medicines.

Impax is a technology based specialty pharmaceutical company.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDNovember 22, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 22, 2011
Words:216
Previous Article:-Deutsche, Emirates NBD, Noor, QInvest to help Albaraka Turk market Islamic bond.
Next Article:Nanometrics announces acquisition of Nanda Technologies of Germany for about USD23m cash.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters